comparemela.com
Home
Live Updates
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints : comparemela.com
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control . – TransCon PTH demonstrated statistically... | March 13, 2022
Related Keywords
Copenhagen ,
Køavn ,
Denmark ,
Germany ,
Japan ,
United States ,
New Jersey ,
Palo Alto ,
California ,
Redwood City ,
Underbjerg ,
Midtjylland ,
Heidelberg ,
Baden Wüberg ,
Berlin ,
Aimee Shu ,
Ascendis Pharma ,
Melinda Baker ,
Tim Lee ,
Outcomes Trust Inc ,
Ascendis Pharma Group ,
Dial In International ,
Patti Bank ,
Ascendis Pharma Hp Patient Experience Research ,
Exchange Commission ,
Us Food Drug Administration For Transcon ,
European Union ,
European Medicines Agency ,
Globenewswire Inc ,
Clinical Development ,
Trial Top Line ,
Composite Endpoint ,
Key Pre Specified Secondary Endpoints ,
Hypoparathyroidism Patient Experience Scales ,
Physical Functioning ,
Daily Life ,
Vice President ,
New Drug Application ,
Drug Administration ,
Marketing Authorisation Application ,
Medicines Agency ,
Japan Trial ,
Eastern Time ,
Ascendi Annual Report ,
Outcomes Trust ,
Clin Endocrinol Metab ,
Ascendis Pharmaas Stock Exchange ,
News ,
Information ,
Press Release ,
Or ,
The ,
Primary ,
Composite ,
Transcon ,
Ith ,
Remonstrated ,
Response ,
Gate ,
F ,
Ompared ,
O ,
Control ,
Emonstrated Asnd Us04351p1012 ,
comparemela.com © 2020. All Rights Reserved.